reference/16825193

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16825193

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1481
issn	0732-183X 1527-7755
issueIdentifier	13
pageRange	1475-1481
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	1475
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_8c485e41acc37667eca30ca80c20af48
bibliographicCitation	Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2015 May 01;33(13):1475–81. PMID: 25512461; PMCID: PMC4881365.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ae8dc955bb0204c2888f96ffbc8b109c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_934bbe27b5f57485b3d2f8b0a619073e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_02168b01e2e8266f3623398352adcd1b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f220160be01e4fa4465c2e2e1b6726e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6ebb0c488dde33e9c3306aec97f04ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90b6dbe0d02ea6677d847f8c04786b6e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_654e2a89bc84ea47b5cf8dc0f3487014 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ea26b711aa33d3a52164c925136d009 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ead2cbe9c12a1f42891b138ffcc8270 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c43bdf3eb8a53582ad24a9d66d128f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fbfa25345d80f6faf79028c67bf4d64d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a18f810357b004b3111a24147aae709c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d6f17ac88f00178b4d6ea92524ce909 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff3cf657db943c9c670b5e92686afd4d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4471acd83ff3a4f4599afab562f7f734 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a77627930637df87cb05a1790ab0168 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d1a97b92b5a663789f17e7d3d9bf23a
date	2015-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2014.55.7504 https://pubmed.ncbi.nlm.nih.gov/PMC4881365 https://pubmed.ncbi.nlm.nih.gov/25512461
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/0732-183X
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
discusses	http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M0016714 http://id.nlm.nih.gov/mesh/M0014907 http://id.nlm.nih.gov/mesh/M0550416
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010190Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D014481 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D009593Q000008 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D010190Q000473 http://id.nlm.nih.gov/mesh/D010190Q000401 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D016016 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D010752Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7548 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID132324 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11984561 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6914 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8766

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID252166895

Total number of triples: 81.